Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of SIR2501 in amyotrophic lateral sclerosis
CTR20253552Phase 2Active
- Sponsor
- Vitality Biopharma, Inc.
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SIR2501 in amyotrophic lateral sclerosis (ALS), sponsored by Vitality Biopharma, Inc.. Started Nov 2025; status: active.
02
Drugs
SIR2501
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on CTR20253552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253552.